|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 910.2 USD | +1.12% |
|
+1.84% | +3.68% |
| Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
Nov 21 (Reuters) - The U.S. Food and Drug Administration on Saturday issued an emergency use authorization for Regeneron Pharmaceuticals Inc's COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
(Reporting by Rama Venkat and Manas Mishra in Bengaluru; Editing by Dan Grebler)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.68% | 96.73B | |
| -0.69% | 103B | |
| +0.96% | 21.31B | |
| -16.38% | 21.21B | |
| -6.45% | 18.79B | |
| -42.14% | 16.37B | |
| -24.26% | 13.68B | |
| +6.85% | 13.44B | |
| +22.24% | 10.98B | |
| -21.78% | 8.56B |
REGENERON PHARMACEUTICALS, INC. 
